Ghent University Hospital is seeking a Head of CellGENTherapies. CellGENTherapies is at the core of the development and production of advanced gene therapy, cell therapy, and tissue-based products, as well as prophylactic RNA vaccines for early-phase (Phase I) clinical studies. The focus is on small-batch production, including personalized therapeutics, within a strongly translational environment. CellGENTherapies…

This September month, Institut Curie, the Princess Máxima Center for pediatric oncology and Hopp Children’s Cancer Center Heidelberg (KiTZ) announce the launch of the European THEODORA project to accelerate the development and clinical evaluation of new immunotherapies against Ewing sarcoma, an aggressive cancer that mainly affects adolescents and young adults. Funded with €13.2 million by…

Vlaanderen investeert sterk in onderzoeksinfrastructuur: geavanceerde labo’s, testfaciliteiten, pilootinstallaties, databanken en digitale platformen die mee het fundament vormen van innovatie en technologische vooruitgang. Deze infrastructuren zijn niet alleen cruciaal voor wetenschappelijk onderzoek, maar bieden ook concrete kansen voor bedrijven die willen innoveren, experimenteren of nieuwe producten en diensten ontwikkelen. Het doel van deze brochure is…

CellGENTherapies is partner in the EU co-funded ATMP XB project, aiming to strengthen the Flemish–Dutch border region as a leading hub for ATMP research and development by providing reliable infrastructure, fostering innovation, building knowledge and creating strong cross-border collaboration. ATMPs (advanced therapy medicinal products) include cell and gene therapies that use living cells or genetically…

In March this year, CellGENTherapies has announced their one full floor new GMP facility in the Nobel Building on Ghent University campus. This initiative is being funded by EFRO, FWO and the Ghent University Hospital. The team has worked hard to review the design plans of the cutting-edge cleanrooms with a focus on optimal processing…

Ghent University Hospital and its GMP facility CellGENTherapies, are partner in an ambitious, international (ATTRACT) study, called ARI-chALL, to investigate whether an innovative, academically developed CAR-T cell therapy can be used in children with acute lymphoblastic leukaemia during their first relapse. The new ARI-chALL study – which will take place in Belgium (Ghent), Spain, the…

Ghent University and CellGENTherapies, the GMP facility of Ghent University hospital, are key partner in ATMP XB, a cross-border initiative between Flanders and the Netherlands. The aim is to accelerate the development, production, and quality control of Advanced Therapy Medicinal Products (ATMPs). ATMP XB includes: The goal is a learning network to address process development…

CellGENTherapies is attracted by the VIB and the Katholieke Universiteit Leuven (Prof Dieter Lambrechts) to produce a lipid nanoparticle RNA cancer vaccine using the Galsome technology developed by Ghent Research Group on Nanomedicines (Prof Stefaan De Smedt and Dr Ine Lentacker) for a clinical trial in patients with hepatocellular carcinoma (PI prof Jeroen Dekervel, UZLeuven).…

Prof Bart Vandekerckhove, head of the GMP unit ‘CellGENTherapies’ of Ugent and UZ Gent, has received an important grant of €790K from ‘the Stichting Tegen Kanker (STK)’ and ‘Kom op tegen Kanker (KOTK)’, both Belgians associations funding research to improve cancer outcome. The grant will be used to setup a Phase I clinical trial of…

On the UZ Gent campus, a new GMP unit is being built, covering no less than 1000 m2 and meeting the latest quality requirements. The new GMP unit will be fully operational by the end of 2026. With the new facilities, the University Hospital of Ghent (UZ Gent) continues to facilitate research into innovative applications…